<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109133">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01730664</url>
  </required_header>
  <id_info>
    <org_study_id>ETB/V0.2</org_study_id>
    <nct_id>NCT01730664</nct_id>
  </id_info>
  <brief_title>PK/PD of Ertapenem In Patients With TB</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Ertapenem in Patients With Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Treatment of multidrug or extensively drug resistant tuberculosis (MDR/XDR-TB) is a real
      challenge as failure in response to treatment and serious side-effects are frequently
      encountered. New, more effective drugs with less side effects are therefore urgently needed
      to solve this problem. Although several new drugs against TB are in the pipeline, physicians
      currently have limited treatment options for treatment of complicated MDR/XDR-TB cases.
      Therefore, drugs developed and labeled for other infectious diseases are evaluated for TB.

      Objective:

      The main objective of this prospective clinical trial is to evaluate pharmacokinetics of a
      standard dose (1000mg) of ertapenem in TB patients. This clinical trial will provide
      important information on PK of ertapenem in TB patients for future studies. Data can be used
      for limited sampling strategies for ertapenem based on a pharmacokinetic population model
      constructed from the full PK curves of the patients.

      Study design:

      A prospective pharmacokinetic study.

      Study population: 12 TB patients.

      Intervention: Single dose of 1000mg in a 30 minutes intravenous infusion.

      Main study parameters/endpoints:

      The pharmacokinetic parameters (Vd, Cl, AUC, etc) of ertapenem are the primary endpoints of
      the study. The T&gt;MIC and AUC0-24h/Minimal inhibitory concentration (MIC) ratio are most
      likely the best predictive parameters for efficacy of ertapenem treatment and will be
      calculated for a range of M tuberculosis isolates.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    problems with drug susceptibility testing of ertapenem
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>first day</time_frame>
    <safety_issue>No</safety_issue>
    <description>main objective of this prospective clinical trial is to evaluate AUC of a standard dose (1000mg) of ertapenem in TB patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: number of patients with organ dysfunction</measure>
    <time_frame>day 1 and day 3</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>renal function(eGFR) and liver enzymes(ALAT; ASAT)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>limited sampling strategies</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>limited sampling strategies for ertapenem based on a pharmacokinetic population model constructed from the full PK curves of the patients.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>PK of Ertapenem in TB Patients</condition>
  <arm_group>
    <arm_group_label>ertapenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose ertapenem</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ertapenem</intervention_name>
    <description>single dose of 1000mg ertapenem IV</description>
    <arm_group_label>ertapenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with TB, with Mycobacterium tuberculosis (or M. africanum) by culture

          -  Adults: from 18 years until 64 years of age

        Exclusion Criteria:

        -Contra-indications for ertapenem:

          -  There are few adverse effects of ertapenem. The only absolute contra- indication is a
             previous anaphylactic reaction to ertapenem or other Î²-lactam antibiotic.

          -  Renal Insufficiency, defined by a eGFR of 30ml/min

          -  Pregnancy

          -  HIV

          -  Body weight &lt; 40 kg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UMCG - Tuberculosis Center</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Tremblay LW, Fan F, Blanchard JS. Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem. Biochemistry. 2010 May 4;49(17):3766-73. doi: 10.1021/bi100232q.</citation>
    <PMID>20353175</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>November 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>JWC Alffenaar</investigator_full_name>
    <investigator_title>PhD PharmD Clinical Pharmacologist</investigator_title>
  </responsible_party>
  <keyword>ertapenem</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
